Age and *Helicobacter pylori* decrease gastric mucosal surface hydrophobicity independently

A Hackelsberger, U Platzer, M Nilius, V Schultze, T Günther, J E Dominguez-Muñoz, P Malfertheiner

Abstract

Background—Gastric mucosal surface hydrophobicity (GMSH) is an essential component of the mucosal defence system that is decreased by *Helicobacter pylori* and non-steroidal anti-inflammatory drugs (NSAIDs). Gastric ulcers occur predominantly in elderly subjects, and may thus reflect diminished mucosal resistance.

Aims—To investigate whether aging decreases GMSH.

Patients—One hundred and twenty patients without peptic ulcer disease were divided into three age groups: I (41 years or below); II (41–64 years); and III (65 years or above).

Methods—Biopsy specimens were taken from the antrum, corpus, and cardia for histology (Sydney system), urease testing for *H. pylori*, and for contact angle measurement of GMSH with a goniometer. The presence of specific *H. pylori* antibodies was checked by immunoblotting.

Results—Fifty two patients (43%) were infected, and 68 were uninfected with *H. pylori*. GMSH at all biopsy sites was lower in *H. pylori* infected subjects ($p=0.0001$), but also decreased with age independently of infection status ($p=0.0001$). The most notable decrease in GMSH occurred between age groups I and II in those with, and between age groups II and III in those without, *H. pylori* infection. GMSH was greater in antral than in corpus mucosa in both infected ($p=0.0001$) and uninfected patients ($p=0.0003$).

Conclusions—A physiological decrease in GMSH with aging may contribute to the risk of ulcer development in the elderly, and may act synergistically with *H. pylori* and/or NSAIDs on gastric mucosal defence.

(Gut 1998;43:465–469)

Keywords: gastric mucosal defence; surface hydrophobicity; aging; *Helicobacter pylori*

The pathogenesis of peptic ulcer disease (PUD) is considered to be an imbalance of defensive and aggressive factors in the upper gastrointestinal tract. *Helicobacter pylori* is a key pathogenetic factor in peptic ulceration¹ as are non-steroidal anti-inflammatory drugs (NSAIDs)²; each factor acts independently of the other. A substantial proportion of gastric ulcer patients may, however, both have *H. pylori*

gastritis and use NSAIDs.³ While gastric acid output may be modified by *H. pylori* gastritis towards either hypersecretion or hyposecretion,^{4–5} it is not altered by NSAIDs. Like *H. pylori* gastritis the latter compromise the “defence line” of the gastric mucosa. The specific hydrophobic property of the gastric mucosa is an essential component of the mucosal barrier and is due to an adsorbed layer of surface active phospholipids (SAPL)⁶ secreted by gastric mucous cells.⁷ Gastric mucosal surface hydrophobicity (GMSH) can be measured reliably and quite simply as the contact angle at which a drop of saline intersects the surface of the gastric mucosa.⁸ This technique has been applied to endoscopic biopsy specimens of gastric mucosa,⁹ and it has been shown that both *H. pylori* gastritis¹⁰ and NSAIDs¹¹ decrease GMSH. While *H. pylori* infection is acquired in childhood in most individuals so affected,^{12–13} gastric ulcer is a disease of the middle aged and the elderly.^{14–16} In patients on NSAID medication the risk of gastric ulcer complications is also clearly increased in the elderly.^{17–18} This investigation therefore addressed the question whether, apart from *H. pylori* infection, aging itself decreases GMSH, and whether differences in GMSH occur in antral, corpus, and cardiac mucosa.

Materials and methods

PATIENT SELECTION

During the eight month period between October 1995 and May 1996, 135 patients undergoing elective upper gastrointestinal endoscopy at our department were recruited. All underwent a standardised interview to check inclusion criteria, and gave their informed consent to the extended biopsy protocol, which was approved by the local hospital ethics committee. Patients with a history of PUD, gastric surgery, malignancy, coagulation disorders, or medication with NSAIDs, corticosteroids, antibiotics, bismuth, histamine H₂ receptor antagonists, or proton pump inhibitors (PPI) during the month preceding endoscopy were excluded, as were those previously examined for *H. pylori* status. We also excluded all smokers, regular drinkers, and patients with severe diseases outside the upper gastrointestinal tract. Four months into the study a provisional analysis of the age distribution of the patients participating showed a preponderance of middle aged subjects; from then only younger or older patients were admitted.

ENDOSCOPY

Endoscopy was performed after an overnight fast. If no significant lesions (ulcers, malignant

Department of
Gastroenterology,
Hepatology, and
Infectious Diseases

A Hackelsberger
U Platzer
M Nilius
V Schultze
J E Dominguez-Muñoz
P Malfertheiner

Department of
Pathology,
Otto-von-Guericke
University,
Magdeburg, Germany
T Günther

Correspondence to:
Professor P Malfertheiner,
Department of
Gastroenterology,
Hepatology, and Infectious
Diseases,
Otto-von-Guericke-University,
Leipziger Strasse 44, 39120
Magdeburg, Germany.

Accepted for publication
23 March 1998

disease, varices, Barrett's oesophagus) were found (up to three chronic erosions were accepted) patients were included. Closely grouped mucosal biopsy specimens were obtained from each gastric compartment with standard forceps: four specimens from the antrum (2 cm from the pylorus), four from the corpus (mid region of the greater curvature), and three from the cardia directly below the squamocolumnar junction. After endoscopy a blood sample was obtained.

GASTRIC MUCOSAL SURFACE HYDROPHOBICITY

The measurement was performed as previously described and validated.⁹ In brief, an unfixed biopsy specimen from each site was rinsed with 0.9% saline, oriented mucosa upwards on a glass slide under a dissecting microscope, and placed on the specimen stage of the goniometer (Rame-Hart 100-00, Mountain Lakes, New York). After 30 minutes air drying, a 0.5 µl drop of 0.9% saline was applied to the mucosal surface and the plateau contact angle at the liquid/solid interface as an index of GMSH was read on the left and right side of the droplet. Three droplets were thus applied to give six measurements on each specimen, and the mean value was calculated. A measurement was judged to be unreliable if variations of more than 5° were found on a biopsy specimen, and the patient was then excluded. The investigator performing the measurements (UP) was unaware of the patient's age.

HISTOLOGY

After fixation in 4% neutral formalin, 4 µm sections from two biopsy specimens obtained from each gastric compartment were prepared by routine methods and stained with modified Giemsa to detect *H pylori* and grade the bacterial density, and with haematoxylin and eosin to grade the degree and activity of gastritis. A four point scale (0–3) was used for all gradings in accordance with the updated Sydney system.¹⁹

ASSESSMENT OF *H PYLORI* INFECTION

We additionally used a previously validated²⁰ rapid urease test (HUT-test, Astra GmbH, Wedel, Germany) for the enzymatic detection of *H pylori* in one antral and one corpus biopsy specimen. We also used a previously validated²¹ commercially available western blot test (Helico-Blot 2.0, Genelabs, Singapore) to detect antibodies to CagA, VacA, and four further specific *H pylori* proteins in all patients. *H pylori* infection was assessed if active gastritis with bacteria of typical shape was shown by histology and/or the rapid urease test read positive. Patients in whom serological but no biopsy based evidence of *H pylori* infection was found were excluded from the evaluation.

STATISTICAL ANALYSIS

Variables associated with GMSH were assessed by analysis of variance (ANOVA), *t* test, and U test and Spearman's correlations using the SPSS package. Significance was considered at a 5% probability level.

Figure 1 Means of contact angles as a function of *H pylori* status and biopsy site.

Results

In eight of 135 patients enrolled the contact angle measurements were considered unreliable on the criteria described earlier. In most of these cases the biopsy specimens had an irregular surface and the patients were excluded. A further seven patients with uncertain *H pylori* status were also excluded. A total of 120 patients (65 females (54%)) with a mean age of 52.2 (19.7) years (range 16–85) were finally evaluated. Fifty two patients (43%) were infected with *H pylori* and were significantly older (mean age 59.4 (17.5) years, $p < 0.0001$) than the 68 uninfected patients (mean age 46.7 (19.6) years).

Multivariate ANOVA revealed that two principal factors were independently associated with GMSH at all biopsy sites: *H pylori* status ($p < 0.0001$) and age ($p < 0.0001$). Figure 1 shows the mean GMSH values of the whole sample measured at the three biopsy sites and subgrouped by *H pylori* status. *H pylori* infection was associated with a significantly decreased GMSH at the three gastric sites. There was no difference in GMSH between male and female subjects in any group (data not given). Small but significant differences were found between the biopsy sites, the contact angles in the antrum being significantly higher than in the corpus or cardia, both in patients with and without *H pylori* infection.

Significant differences are as follows. At all sites: *H pylori* negative greater than *H pylori* positive (all $p < 0.0001$). Infected patients: antrum greater than corpus ($p = 0.0001$), antrum greater than cardia ($p = 0.0362$), cardia greater than corpus ($p = 0.0041$). Uninfected patients: antrum greater than corpus ($p = 0.0003$), antrum greater than cardia ($p = 0.0017$).

To evaluate the age dependency of GMSH, three groups of equal size ($n = 40$) were formed to reflect the age distribution in the entire study population: group I (41 years or below); II (41–64 years); and III (65 years or above). On account of the well known age cohort effect the percentage of *H pylori* infected patients increased through the groups, from 22.5% to 42.5% to 65%, respectively. Figure 2 shows the mean GMSH contact angles measured at the three biopsy sites subgrouped by age (groups I–III) for patients without (fig 2A) and those with *H pylori* infection (fig 2B). On comparison of *H pylori* patients in age groups I and II, a significant decrease in GMSH was seen in the antrum only, while the decrease noted in

Table 1 Means of contact angles in age groups I and III at the three gastric biopsy sites

	Group I (n=40) <i>H pylori</i> positive (n=9, 22.5%)	Group III (n=40) <i>H pylori</i> positive (n=26, 65%)	p Value
Antrum			
<i>H pylori</i> negative	71.0 (4.8, 69.2-72.8)	65.5 (3.4, 63.5-67.4)	<0.0001
<i>H pylori</i> positive	66.6 (2.5, 64.6-68.5)	61.5 (3.7, 60.0-63.1)	0.001
Corpus			
<i>H pylori</i> negative	69.3 (4.9, 67.5-71.1)	64.9 (4.1, 62.6-67.3)	0.005
<i>H pylori</i> positive	63.3 (3.1, 60.9-65.7)	60.5 (3.4, 59.1-61.9)	0.041
Cardia			
<i>H pylori</i> negative	69.6 (5.3, 67.6-71.6)	63.4 (2.3, 62.1-64.8)	<0.0001
<i>H pylori</i> positive	65.0 (2.8, 62.9-67.2)	61.1 (2.5, 60.1-62.1)	0.003

Results are expressed as mean (SD, 95% confidence interval).

corpus and cardiac mucosa almost reached the level of significance. In uninfected patients, however, no effect was shown. Comparison of age groups II and III, in contrast, showed a significant decrease in contact angles in antral, corpus, and cardiac mucosa only in the absence of *H pylori* while only a minor decrease is seen in *H pylori* patients. Comparison of the age groups I and III clearly showed the effect of aging both in patients with and without *H pylori* gastritis (table 1): significant decreases in mean GMSH values were found in antral, corpus, and cardiac mucosa. Figure 4 also illustrates this finding and shows the age dependent decrease in GMSH values measured in antral biopsy specimens from our overall study population subgrouped by *H pylori* status. As shown in fig 3 and by the SD values in fig 2, there were a few outliers with exceptionally low contact angles, especially among younger uninfected subjects. As all patients had undergone an interview to exclude

Figure 2 (A) Mean contact angles (SD) at the three biopsy sites in patients without *H pylori* infection as a function of age. Group I (n=31), Group II (n=23), Group III (n=14). (B) Mean contact angles (SD) at the three biopsy sites in patients with *H pylori* infection as a function of age. Group I (n=9), Group II (n=17), Group III (n=26).

Figure 3 Contact angle values as a measure of GMSH in antral mucosa according to age and *H pylori* infection.

Table 2 Mean (SD) scores (Sydney System) for bacterial density, and active and chronic gastritis in 52 *H pylori* infected patients

	Antrum	Corpus	Cardia
<i>H pylori</i> density	1.6 (0.6)	1.5 (0.9)	1.2 (0.7)
Active gastritis	1.5 (0.6)	1.4 (0.7)	1.3 (0.5)
Chronic gastritis	2.1 (0.6)	1.8 (0.6)	1.9 (0.5)

Significant differences are as follows: *H pylori* density: antrum > cardia (p=0.001), corpus > cardia (p=0.048); chronic gastritis: antrum > corpus (p=0.002), antrum > cardia (p=0.025).

the existence of factors known to influence hydrophobicity, we must ascribe this variation to unknown endogenous factors.

Histology in uninfected patients revealed no or only mild chronic inflammation (data not given). The mean scores of the *H pylori* infected patients (table 2) revealed histological differences between the gastric sites with higher bacterial density and more notable chronic inflammation in antral compared with corpus or cardiac mucosa. Comparison of the histological scores in age groups I, II, and III revealed a slight, though insignificant (p<0.1), increase with age in bacterial density and active gastritis only in the corpus (detailed data not given). On evaluating all 52 *H pylori* infected patients together, no significant association between GMSH and any of the histological variables was shown. On evaluating the age groups separately, however, group II showed a significant inverse relation between antral GMSH and the antral density of *H pylori* (r=-0.545, p=0.024). No such correlations between GMSH and histology existed in corpus or cardiac mucosa. Analysis of the data revealed no outlying GMSH values associated with mucosal atrophy and/or intestinal metaplasia, neither of which was commonly seen in our sample (data not given). Of 52 infected patients, 30 (57.7%) were seropositive for CagA and 21 (40.4%) were seropositive for VacA by immunoblotting. However, neither marker of bacterial virulence showed any significant association with GMSH regardless of biopsy site (data not given).

Discussion

This study confirms earlier reports of reduced GMSH in *H pylori* infected patients.^{10 22} It has recently been reported²³ that GMSH in antral

biopsy specimens of infected patients was inversely related to the bacterial density in antral histology; in our sample this association was confirmed only in middle aged subjects. In addition we have established for the first time that in humans GMSH decreases with age independently of *H. pylori* status, the effect being seen equally in infected and uninfected individuals. Aging may therefore be added to *H. pylori* positive gastritis and NSAID medication as a factor impacting on gastric mucosal resistance. Our data show that this decrease in GMSH occurs at a younger age in *H. pylori* infected as compared with uninfected patients (figs 2 and 3). The most notable decrease in GMSH was seen between younger and middle aged *H. pylori* positive patients and apparently slowed above the age of 65, while the histological severity of gastritis remained largely unchanged. In uninfected patients, however, the decrease was only seen in the elderly. It therefore seems possible that *H. pylori* infection aggravates and antedates a physiological impairment of mucosal resistance.

It has been shown in rabbits that GMSH is subject to maturation changes. In rabbit corpus mucosa the mean contact angle in suckling animals (76.4°) increases after weaning (84.2°) but decreases sharply in adult animals (36.1°).²⁴ According to the commonly accepted model proposed by Lichtenberger *et al*, GMSH is determined by a mucous gel layer of adsorbed surface active phospholipids (SAPL).⁶ A phospholipid rich zone in the apical region of surface mucous cells has been shown ultrastructurally in endoscopic gastric biopsy specimens,²⁵ and these phospholipids are a secretory component of gastric mucous cells.⁷ A topical enhancement of hydrophobicity by oral SAPL, either in the form of a liposomal suspension or in milk has been shown in animal studies.^{6, 26–28} Thus an examination of GMSH in relation to dietary habits (consumption of dairy products) might be worthwhile. As all the patients in this study were investigated after an overnight fast, however, it is possible that acute nutritional influences could account for the variation of GMSH found in our sample.

Several studies on cultured gastric mucous cells have shown that prostaglandins (PGE₂) stimulate the synthesis of SAPL.^{29–30} In the rat and canine gastric mucosa PGE₂ has been shown to increase hydrophobicity and reverse the hydrophobicity reduced by aspirin.^{31–33}

Several studies have investigated the effect of aging on gastric mucosal prostaglandin concentrations. An earlier study investigated the synthesis and catabolism of mucosal PGE₂ in patients with gastritis and peptic ulcer, and found no clear correlation with age.³⁴ More recently, two groups have reported a significant decrease in gastric mucosal prostaglandin content in the elderly.^{35–36} One of these studies³⁶ investigated asymptomatic patients with no history of PUD or NSAID usage and took the *H. pylori* status into account. Significantly decreased concentrations of PGE₂ and PGF_{2α} were found in the elderly compared with younger patients. The mean PGE₂ levels were

higher in antral than in fundic mucosa, but this finding was not reported to be significant. Two studies investigating rat gastric mucosa found that mucosal prostaglandin synthesis decreased with age.^{37–38} A further mechanism relating to the age dependent decrease in GMSH might be the observation of a reduction in the number of epithelial cells in aged rats³⁹ and of mucous cells in the gastric mucosa of elderly patients.⁴⁰ However, these morphological changes may well be linked to a decrease in gastric mucosal prostaglandin concentrations in the elderly.⁴¹ In conclusion, the decreasing prostaglandin concentrations in the gastric mucosa of the elderly would seem to be a plausible explanation for the age dependent decrease in GMSH found in the present study.

This study shows that *H. pylori* gastritis weakens the mucosal defence in the cardia region, as also occurs in the corpus and antrum.⁴² In many infected patients, however, the bacterial density was higher and the mucosal inflammation more notable in the antrum than in corpus or cardia. This might explain in part, why in *H. pylori* positive patients the decline in GMSH with age was less pronounced in corpus than in antral mucosa. Furthermore, GMSH was higher in antral than in corpus mucosa in both *H. pylori* infected and uninfected patients. Such differences were not observed in the first study using endoscopic biopsy specimens of human gastric mucosa,⁹ but antral was found to be higher than corpus GMSH in both the pig⁴³ and the rabbit.²⁴ Although our data cannot shed much light on these differences we suspect that they might in part be physiological. The differing amounts of mucus secreting versus specific (parietal and chief) cells in the antral and oxyntic mucosa⁴⁴ might be a possible explanation.

In summary, aging reduces gastric mucosal surface hydrophobicity. This may act synergistically with the injurious effects of *H. pylori* gastritis and such exogenous compounds as NSAIDs on gastric mucosal defence and contribute to the higher risk for gastric ulcer development in the elderly. The hypothesis that gastric ulcer formation is more likely when gastric mucosal hydrophobicity falls short of a threshold level needs to be investigated further.

- 1 NIH Consensus conference. Helicobacter pylori in peptic ulcer disease. *JAMA* 1994;272:65–9.
- 2 Fries JF, Miller SR, Spitz PW, *et al*. Towards an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. *Gastroenterology* 1989;96:547–55.
- 3 Al-Assi MT, Genta RM, Karttunen TJ, *et al*. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. *Endoscopy* 1996;28:229–33.
- 4 El-Omar EM, Penman IA, Ardill JES, *et al*. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. *Gastroenterology* 1995;109:681–91.
- 5 Ruiz B, Correa P, Fonthan E, *et al*. Antral atrophy, Helicobacter pylori colonization and gastric pH. *Am J Clin Pathol* 1996;105:96–101.
- 6 Lichtenberger LM, Graziani LA, Dial EJ, *et al*. Role of surface active phospholipids in gastric cytoprotection. *Science* 1983;219:1327–9.
- 7 Kao YC, Lichtenberger LM. Localization of phospholipid-rich zones in rat gastric mucosa: possible origin of a protective hydrophobic luminal lining. *J Histochem Cytochem* 1987;35:1285–98.
- 8 Hills BA, Butler BD, Lichtenberger LM. Gastric mucosal barrier: the hydrophobic lining to the lumen of stomach. *Am J Physiol* 1983;244:G561–8.
- 9 Spychal RT, Marrero JM, Savarymattu SH, *et al*. Measurement of surface hydrophobicity of human gastrointestinal mucosa. *Gastroenterology* 1989;97:104–11.

- 10 Spychal RT, Goggin PM, Marrero JM, *et al.* Surface hydrophobicity of gastric mucosa in peptic ulcer disease—relationship to gastritis and *Campylobacter pylori* infection. *Gastroenterology* 1990;**98**:1250–4.
- 11 Goddard PJ, Hills BA, Lichtenberger LM. Does aspirin damage canine gastric mucosa by reducing surface hydrophobicity? *Am J Physiol* 1987;**252**:G421–30.
- 12 Mendall MA, Goggin PM, Molineaux N, *et al.* Childhood living conditions and *Helicobacter pylori* seropositivity in adult life. *Lancet* 1992;**339**:896–7.
- 13 Cullen DJ, Collins BJ, Christiansen KJ, *et al.* When is *Helicobacter pylori* infection acquired? *Gut* 1993;**34**:1681–2.
- 14 Kurata JH. Ulcer epidemiology: an overview and proposed research framework. *Gastroenterology* 1989;**96**(suppl):569–80.
- 15 Sipponen P, Seppälä K, Äärinen M, *et al.* Chronic gastritis and gastroduodenal ulcer: a case control study on the risk of coexisting duodenal or gastric ulcer in patients with gastritis. *Gut* 1989;**30**:922–9.
- 16 Lindell G, Celebioglu F, Stael von Holstein C, *et al.* On the natural history of peptic ulcer. *Scand J Gastroenterol* 1994;**29**:979–82.
- 17 Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1991;**115**:787–96.
- 18 Schubert TT, Bologna SD, Nensley Y, *et al.* Ulcer risk factors: interactions between *Helicobacter pylori* infection, nonsteroidal use and age. *Am J Med* 1993;**94**:413–18.
- 19 Dixon MF, Genta RM, Yardley JH, Correa P, and the participants in the international workshop on the histopathology of gastritis. Classification and grading of gastritis: the updated Sydney system. *Am J Surg Pathol* 1996;**20**:1161–81.
- 20 Malfertheiner P, Dominguez-Munoz JE, Heckenmüller H, *et al.* Modified rapid urease test for detection of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 1996;**8**:53–6.
- 21 Glupczynski Y, Vandenborre C, Goutier S, *et al.* Evaluation of Helicoblot 2.0—a new commercial Western blot test—for the serological diagnosis of *Helicobacter pylori* infection [abstract]. *Gut* 1995;**37**(suppl 1):A59.
- 22 Goggin PM, Marrero JM, Spychal RT, *et al.* Surface hydrophobicity of gastric mucosa in *Helicobacter pylori* infection: effect of clearance and eradication. *Gastroenterology* 1992;**103**:1486–90.
- 23 Asante M, Ahmed H, Patel P, *et al.* Gastric mucosal hydrophobicity in duodenal ulceration: role of *Helicobacter pylori* infection density and mucus lipids. *Gastroenterology* 1997;**113**:449–54.
- 24 Mack DR, Neumann AW, Policova Z, *et al.* Surface hydrophobicity properties of rabbit stomach in vitro. *Pediatr Res* 1994;**35**:209–13.
- 25 Mauch F, Bode G, Ditschuneit H, *et al.* Demonstration of a phospholipid rich zone in the human gastric epithelium damaged by *Helicobacter pylori*. *Gastroenterology* 1993;**105**:1698–704.
- 26 Dial EJ, Lichtenberger LM. A role for milk phospholipids in protection against gastric acid. Studies in adult and suckling rats. *Gastroenterology* 1984;**87**:379–85.
- 27 Dial EJ, Lichtenberger LM. Milk protection against experimental ulcerogenesis in rats. *Dig Dis Sci* 1987;**32**:1145–50.
- 28 Kiviluoto T, Paimela H, Mustonen H, *et al.* Exogenous surface active phospholipid protects *Necturus* gastric mucosa against luminal acid and barrier-breaking agents. *Gastroenterology* 1991;**100**:38–46.
- 29 Scheiman JM, Kraus ER, Bonville LA, *et al.* Synthesis and prostaglandin E_2 induced secretion of surfactant phospholipid by isolated gastric mucous cells. *Gastroenterology* 1991;**100**:1232–40.
- 30 Bernhard W, Schulte H, Piller M, *et al.* Synthesis and release of phosphatidylcholine by isolated porcine gastric mucous cells in primary culture. *Eur J Clin Invest* 1996;**26**:797–802.
- 31 Lichtenberger LM, Richards JE, Hills BA. Effect of 16,16-dimethyl prostaglandin E_2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa. *Gastroenterology* 1985;**88**:308–14.
- 32 Dial EJ, Lichtenberger LM. Surface hydrophobicity in the developing rat. Effects of corticosteroids, thyroxine and prostaglandin E_2 . *Gastroenterology* 1988;**94**:57–61.
- 33 Goddard PJ, Kao YC, Lichtenberger LM. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. *Gastroenterology* 1990;**98**:361–70.
- 34 Hawkey CJ. Synthesis of prostaglandin E_2 , thromboxane B_2 and prostaglandin catabolism in gastritis and gastric ulcer. *Gut* 1986;**27**:1484–92.
- 35 Goto H, Sugiyama S, Ohara A, *et al.* Age-associated decreases in prostaglandin contents in human gastric mucosa. *Biochem Biophys Res Commun* 1992;**186**:1443–8.
- 36 Cryer B, Redfern JS, Goldschmidt M, *et al.* Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. *Gastroenterology* 1992;**102**:118–23.
- 37 Uchida M, Kawano O, Misaki N, *et al.* Healing of acetic acid-induced gastric ulcer and gastric mucosal PGI_2 level in rats. *Dig Dis Sci* 1990;**35**:80–5.
- 38 Lee M, Feldman M. Age-related reductions in gastric mucosal prostaglandin levels increase susceptibility to aspirin-induced injury in rats. *Gastroenterology* 1994;**107**:1746–50.
- 39 Majumdar AP, Jasti S, Hatfield JS, *et al.* Morphological and biochemical changes in gastric mucosa of aging rats. *Dig Dis Sci* 1990;**35**:1364–70.
- 40 Farinati F, Formentini S, Della-Libera G, *et al.* Changes in parietal and mucous cell mass in the gastric mucosa of normal subjects with age: a morphometric study. *Gerontology* 1993;**39**:146–51.
- 41 Majumdar AP, Fligiel SE, Jaszewski R. Gastric mucosal injury and repair: effect of aging. *Histol Histopathol* 1997;**12**:491–501.
- 42 Hackelsberger A, Günther T, Schultze V, *et al.* Prevalence and pattern of *Helicobacter pylori* gastritis in the gastric cardia. *Am J Gastroenterol* 1997;**92**:2220–4.
- 43 Goggin PM, Ahmed H, Northfield TC. Molecular basis for gastric mucosal hydrophobicity. *Gastroenterology* 1990;**98**(suppl):A49.
- 44 Hogben AMC, Kent TH, Woodward PA, *et al.* Quantitative histology of the gastric mucosa: man, dog, cat, guinea pig and frog. *Gastroenterology* 1974;**67**:1143–54.